Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $34 from $32 and keeps an Outperform rating on the shares. The firm updated its model following the return of DNL-593 from Takeda Pharmaceuticals giving them full control of the FTD-GRN program.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
- Denali Therapeutics price target raised to $39 from $38 at BTIG
- Denali Therapeutics regains full rights to DNL593
- Denali Regains DNL593 Rights After Takeda Collaboration Ends
- Denali Therapeutics Secures $200 Million Royalty Funding